Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known.

Related collections

Author and article information

Journal

PubMed ID:: 26378978

DOI:: 10.1056/NEJMoa1504720

Data availability:

Comments

Comment on this article

scite_

10,525

304

10,095

Smart Citations

10,525

304

10,095

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

Cited by 4,268

See all cited by